Evidence map›Paper›PMID 41068978›Full record

ArticleEuropean journal of medical research2025

Epigenetic and transcriptomic analysis revealed ceRNA regulatory network in glioblastoma multiforme.

Zhenghui Li, Yanqing Li, Jenna Z Liang, Tianxiang Geng, Jing Chen, Yangyang Yuan, Yufang Sui, Wanhong Zhang, Qian Chen, Guowei Tan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhenghui Li *Department of Neurosurgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China.
Yanqing Li *Department of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Jenna Z LiangPhillips Academy, 7 Chapel Ave, Andover, MA, 01810, USA.
Tianxiang GengDepartment of Biomaterials, Faculty of Dentistry, University of Oslo, 0455, Oslo, Norway.
Jing ChenDepartment of Neurosurgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China.
Yangyang YuanDepartment of Clinical Research and Translational Medicine, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China.
Yufang SuiDepartment of Child Developmental Behavior, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Wanhong ZhangDepartment of Neurosurgery, Kaifeng Central Hospital, Kaifeng, 475000, Henan, People's Republic of China.
Qian ChenDepartment of Neurosurgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China.
Guowei TanDepartment of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China. gwtanxm@163.com.
Qiao ShanDepartment of Neurosurgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China. shan_qiao@163.com.

Funding

PhD Research Startup Foundation of the Third Affiliated Hospital of Zhengzhou University BS20230111
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is one of the most common cancers among malignant tumors, and extensive evidence suggests that the prognosis of various human cancers is associated with DNA methylation. Therefore, we analyzed potential GBM prognostic biomarkers by combining GBM methylation sequencing data and transcriptome sequencing data. Biostatistical analysis of the expression of three RNA types (long non-coding RNA, microRNA, and mRNA) from The Cancer Genome Atlas (TCGA) was performed to determine the correlation between NACAD and GBM prognosis. Additionally, we predicted and validated a competitive endogenous RNA (ceRNA) regulatory network associated with epigenetic DNA methylation modifications. The ceRNA regulatory network (DCTN1-AS1-hsa-let-7a-5p-NACAD) was found to be related to overall survival (OS) and disease-specific survival (DSS) of GBM. Furthermore, we identified NACAD as an independent prognostic factor for both GBM OS and DSS. In summary, comprehensive analysis of methylation and transcriptome data led to the identification of genes and pathways in different GBM subtypes, highlighting prognostic genes and ceRNA regulatory networks, and proposing potential candidates.

Indexed as

Brain NeoplasmsEpigenesis, GeneticGene Regulatory NetworksGlioblastomaTranscriptomeBiomarkers, TumorDNA MethylationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMicroRNAsPrognosisRNA, Competitive EndogenousRNA, Long NoncodingBiomarkers, TumorMicroRNAsRNA, Competitive EndogenousRNA, Long NoncodingRNA, Messenger

Identifiers

PMID41068978
PMCPMC12513008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.